Publications by authors named "Nanni Huser"

Claim this Profile
1
18F-FLT PET, a Noninvasive Pharmacodynamic Biomarker of Tumor Cell Proliferation, Detected Differential Response to Various Cyclin-Dependent Kinase (CDK) Inhibitors.
Anand Giddabasappa, Ziyue Karen Jiang, Bing Yang, Laigao Chen, Feng Liu, Nanni Huser

Mol Cancer Ther· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CDK4 selective inhibition improves preclinical anti-tumor efficacy and safety.
Cynthia L Palmer, Britton Boras, Bernadette Pascual, Na Li, Danan Li, Nanni Huser

Cancer Cell· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expanding control of the tumor cell cycle with a CDK2/4/6 inhibitor.
Kevin Freeman-Cook, Robert L Hoffman, Nichol Miller, Jonathan Almaden, John Chionis, Nanni Huser

Cancer Cell· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of PF-06873600, a CDK2/4/6 Inhibitor for the Treatment of Cancer.
Kevin D Freeman-Cook, Robert L Hoffman, Douglas C Behenna, Britton Boras, Jordan Carelli, Nanni Huser

J Med Chem· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A quantitative LC-MS/MS approach for monitoring 2'-fluoro-2'-deoxy-D-glucose uptake in tumor tissue.
Wenlin Li, Cathy Zhang, Nanni Huser, Chad Ray, Scott Fountain

Bioanalysis· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gemtuzumab Ozogamicin (GO) Inclusion to Induction Chemotherapy Eliminates Leukemic Initiating Cells and Significantly Improves Survival in Mouse Models of Acute Myeloid Leukemia.
Cathy C Zhang, Zhengming Yan, Bernadette Pascual, Amy Jackson-Fisher, Donghui Stephen Huang, Nanni Huser

Neoplasia· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Purine Nucleotide Availability Regulates mTORC1 Activity through the Rheb GTPase.
Natasha Emmanuel, Shoba Ragunathan, Qin Shan, Fang Wang, Andreas Giannakou, Nanni Huser

Cell Rep· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel CXCR4 antagonist IgG1 antibody (PF-06747143) for the treatment of hematologic malignancies.
Shu-Hui Liu, Yin Gu, Bernadette Pascual, Zhengming Yan, Max Hallin, Nanni Huser

Blood Adv· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemia.
Manoj K Kashyap, Carlos I Amaya-Chanaga, Deepak Kumar, Brett Simmons, Nanni Huser

J Hematol Oncol· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combined inhibition of EGFR and CK2 augments the attenuation of PI3K-Akt-mTOR signaling and the killing of cancer cells.
Joshua Bliesath, Nanni Huser, Mayuko Omori, Daniel Bunag, Chris Proffitt

Cancer Lett· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of CX-5461, the First Direct and Selective Inhibitor of RNA Polymerase I, for Cancer Therapeutics.
Mustapha Haddach, Michael K Schwaebe, Jerome Michaux, Johnny Nagasawa, Sean E O'Brien, Nanni Huser

ACS Med Chem Lett· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53.
Megan J Bywater, Gretchen Poortinga, Elaine Sanij, Nadine Hein, Abigail Peck, Nanni Huser

Cancer Cell· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CK2 inhibitor CX-4945 suppresses DNA repair response triggered by DNA-targeted anticancer drugs and augments efficacy: mechanistic rationale for drug combination therapy.
Adam Siddiqui-Jain, Joshua Bliesath, Diwata Macalino, Mayuko Omori, Nanni Huser

Mol Cancer Ther· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy.
Adam Siddiqui-Jain, Denis Drygin, Nicole Streiner, Peter Chua, Fabrice Pierre, Nanni Huser

Cancer Res· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo.
Sean G Buchanan, Jorg Hendle, Patrick S Lee, Christopher R Smith, Pierre-Yves Bounaud, Nanni H Huser

Mol Cancer Ther· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90.
Karen Lundgren, Hong Zhang, John Brekken, Nanni Huser, Rachel E Powell

Mol Cancer Ther· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis